Flagship Pioneering Fund VII General Partner LLC
SEC-identified person · CIK 1805917 Identifier-verified
Public-company roles (from insider filings)
| Company | Capacity as filed | Filings |
|---|---|---|
| Generate Biomedicines, Inc. GENB | Officer | filed 2026 - 2026 |
| Foghorn Therapeutics Inc. FHTX | Director | filed 2024 - 2026 |
| Sana Biotechnology, Inc. SANA | Officer | filed 2024 - 2024 |
| Evelo Biosciences, Inc. EVLO | Officer | filed 2022 - 2023 |
| Omega Therapeutics, Inc. OMGA | Officer | filed 2023 - 2023 |
| Seres Therapeutics, Inc. MCRB | Officer | filed 2022 - 2022 |
All roles under one Commission-assigned identifier - the same person by the SEC's own record, not by name matching. From the SEC's insider-transaction filings (Forms 3, 4 and 5). Every reporting director and officer carries a Commission-assigned identifier (CIK), so these footprints are identifier-verified - no name matching involved. Insiders file when they transact, so dates are filing dates: "last filed" never means "served until". This layer is not yet joined to the nonprofit register - identity joins ship only after independent review.